Oramed Pharmaceuticals Valuation
| ORMP Stock | USD 3.17 0.08 2.46% |
At this time, the company appears to be undervalued. Oramed Pharmaceuticals holds a recent Real Value of $3.43 per share. The prevailing price of the company is $3.17. Our model determines the value of Oramed Pharmaceuticals from analyzing the company fundamentals such as Return On Equity of 0.24, shares outstanding of 39.8 M, and Operating Margin of (6.51) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Oramed Pharmaceuticals' valuation include:
Price Book 0.6383 | Enterprise Value | Enterprise Value Ebitda 0.5244 | Price Sales 63.1594 | Trailing PE 3.17 |
Undervalued
Today
Please note that Oramed Pharmaceuticals' price fluctuation is unstable at this time. Calculation of the real value of Oramed Pharmaceuticals is based on 3 months time horizon. Increasing Oramed Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Oramed Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 3.17, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.17 | Real 3.43 | Target 3.25 | Hype 3.18 |
The intrinsic value of Oramed Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Oramed Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Oramed Pharmaceuticals helps investors to forecast how Oramed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oramed Pharmaceuticals more accurately as focusing exclusively on Oramed Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Oramed Pharmaceuticals' intrinsic value based on its ongoing forecasts of Oramed Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Oramed Pharmaceuticals' closest peers.
Oramed Pharmaceuticals Cash |
|
Oramed Pharmaceuticals Total Value Analysis
Oramed Pharmaceuticals is now expected to have valuation of (4.07 M) with market capitalization of 126.32 M, debt of 372 K, and cash on hands of 133.91 M. The negative valuation of Oramed Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Oramed Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(4.07 M) | 126.32 M | 372 K | 133.91 M |
Oramed Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Oramed is to check how much profit was generated for every dollar of assets it reports. Oramed Pharmaceuticals holds a negative application of assets of -0.0422 pct., losing $4.22E-4 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Oramed Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Oramed Pharmaceuticals Profitability Analysis
Based on Oramed Pharmaceuticals' profitability indicators, Oramed Pharmaceuticals' profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess Oramed Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 2005-06-30 | Previous Quarter 13.3 M | Current Value 48.4 M | Quarterly Volatility 7.1 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.65 | 0.87 |
|
|
For Oramed Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oramed Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oramed Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oramed Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oramed Pharmaceuticals over time as well as its relative position and ranking within its peers.
Oramed Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Oramed Pharmaceuticals is estimated to be 0.0 with future projections ranging from a low of 0.0 to a high of 0.0. Oramed Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at 1.0. Please be aware that the consensus of earnings estimates for Oramed Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Oramed Pharmaceuticals Earnings Estimation Breakdown
The calculation of Oramed Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Oramed Pharmaceuticals is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Oramed Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Oramed Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Oramed Pharmaceuticals' value are higher than the current market price of the Oramed Pharmaceuticals stock. In this case, investors may conclude that Oramed Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Oramed Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of August 2024 | Current EPS (TTM) | |
| 0 | 31.77% | 0.26 | 0.0 | 1.0 |
Oramed Pharmaceuticals Ownership Allocation
Oramed Pharmaceuticals owns a total of 39.8 Million outstanding shares. Oramed Pharmaceuticals holds 14.6 pct. of its outstanding shares held by insiders and 23.29 pct. owned by third-party entities. On February 26, 2025, Representative Brad Knott of US Congress acquired $15k to $50k worth of Oramed Pharmaceuticals's common stock.Oramed Pharmaceuticals Profitability Analysis
Net Loss for the year was (19.06 M) with profit before overhead, payroll, taxes, and interest of 13 K.Oramed Pharmaceuticals Past Distributions to stockholders
About Oramed Pharmaceuticals Valuation
The stock valuation mechanism determines Oramed Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Oramed Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Oramed Pharmaceuticals. We calculate exposure to Oramed Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Oramed Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -221.9 K | -210.9 K | |
| Pretax Profit Margin | 3.42 | 3.59 | |
| Operating Profit Margin | (13.53) | (14.21) | |
| Net Profit Margin | 3.71 | 3.90 | |
| Gross Profit Margin | 0.87 | 0.65 |
A single share of Oramed Pharmaceuticals represents a small ownership stake in the entity. As a stockholder of Oramed, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Oramed Pharmaceuticals Dividends Analysis For Valuation
Please note that Oramed Pharmaceuticals has scaled down on payment of dividends at this time. As of 02/12/2026, Retained Earnings is likely to grow to about (151 M). In addition to that, Earnings Yield is likely to grow to -0.21
There are various types of dividends Oramed Pharmaceuticals can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Oramed shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Oramed Pharmaceuticals directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Oramed pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Oramed Pharmaceuticals by the value of the dividends paid out.
Oramed Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Oramed Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 40.8 M | |
| Quarterly Earnings Growth Y O Y | 0.409 |
Oramed Pharmaceuticals Current Valuation Indicators
Oramed Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Oramed Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Oramed Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Oramed Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Oramed Pharmaceuticals' worth.Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.